E N D
1. AMYLOIDOSIS Senior Talk
Collins Okolie PGY3
2. OBJECTIVES Definition
Mechanism of formation
Characteristics common to all amyloid subtypes
Classification
Clinical Importance/Symptoms
Diagnosis and Treatment
Take home message
3. Definition A medical condition resulting from aggregation of extracellularly deposited abnormal proteins called amyloid fibrils that cause damage to organs and tissues.
These fibrils are insoluble, linear, rigid and measures approximately 7.5 to 10mm in width
4. Mechanism of formation Amyloid fibrils arise from misfolded proteins. Alpha helix to beta pleated sheet
Proteins are deposited extracellularly
Proteins aggregate and form fibrils called amyloid fibrils.
Misfolded proteins may result from point mutations.
Deposited as localized vs systemic
-localized; close to cells producing it.
-Systemic; distant sites from these cells producing these abnormal proteins.
5. In 1854 Rudolph Virchow named it amyloid based on color after staining these proteins with iodine and sulfuric acid. Meaning cellulose or starch
6. Characteristics common to all amyloid subtypes Hematoxylin and Eosin (HE) staining results in amorphous eosinophilic appearance when viewed on light microscopy.
7.
Amorphous eosinophilic interstitial amyloid observed on renal biopsy
Picture was adapted from Bruce A Baethge. Amyloidosis Overview. www.emedicine.medscape.com
8. Congo red staining results in bright green fluorescence/birefringe apple green color when viewed under polarized light.
9.
Congo red staining of a cardiac biopsy specimen containing amyloid, viewed under polarized light
Picture was adapted from Bruce A Baethge. Amyloidosis Overview. www.emedicine.medscape.com
10. Electron microscopy shows regular fibrillar structure
X-ray diffraction shows beta pleated sheet structure
11. Classification: Historical vs Modern Historical (Clinical): Primary, Secondary, multiple myeloma associated, Familial.
Modern (Biochemical): Since 1960s based on ability to solubilize fibrils and immunostain for protein subtypes.
23 different human subtypes named based on A for amyloid followed the precursor protein e.g AL, AH.
13. Further Clinical Manifestations CNS/Neuro: Neuropathy both autonomic and peripheral, dementia. Corneal deposits also.
Cardiac:
-Cardiomyopathy typically restrictive
-Heart failure predominantly right sided
-Angina
-Sudden death
-Syncope/pre-syncope
-ECG Abnormalities and Conduction disease
-Arrhythmia
-Cardiac tamponade occasionally, though uncommon.
-Hypotension
15. Pulmonary:
-Pleural effusions
-Parenchymal nodules
-Tracheal and bronchial infiltration causing hoarseness, airway obstruction and dysphagia.
Renal: Proteinuria, nephrotic syndrome, renal failure leading to kidney transplant or dialysis.
16.
Heme: Bleeding abnormalities
Musc: Hypertrophy of muscles, macroglossia
Skin: Nodules, plaques, easy bruising
GI: Organomegaly (Hepatomegaly, splenomegaly), gastroparesis, abnormal bowel movement usually constipation, malabsorption
17. Liver amyloid
18. Diagnosis Unexplained medical disorder and you suspect amyloidosis: e.g heart failure, proteinuria, hepatic dysfunction
Check ECG, TTE, BNP, UPEP, SPEP
Ultimately, you need Tissue biopsy: Abd fat pad, rectal, salivary gland, endomyocardium.
Bone marrow biopsy
19. Treatment Treatment of this medical disorder is limited and research is still in progress.
Treatment differs depending on subtype.
AL and AH
-High dose mephalan plus dexamethasone/prednisone
-In selected candidates autologous stem cell transplant is an option.
- The goal with treatment is to get rid of clonal plasma cells that lead to immunoglobulin protein
20. AA: Treat the infection or chronic inflammatory condition causing apo serum A protein elevation.
Familial Mediterranean fever: Colchicine
Other conditions are treated conservatively or require organ transplant
Prognosis is poor with this medical disorder.
21. TAKE HOME MESSAGE Can affect any organ system
Hematoxylin and Eosin (HE) and Congo stain only tells you these are amyloid fibrils
Need to immunostain to determine subtype
Different subtypes are treated differently.
A lot still have to be known about the therapy as prognosis is poor for this disease.
22. References Rajkumar, S. V. and M. A. Gertz. Advances in the Treatment of Amyloidosis. NEJM. 2007. 356: 2413-2415
Merlini G and V Bellotti. Molecular Mechanisms of Amyloidosis. New England Journal of Medicine 2003, August: 349:583
Baethge B. Amyloidosis Overview. www.emedicine.medscape.com
Bogov B, Lubomirova M and Kiperova B. Biopsy of subcutaneous fatty tissue for diagnosis of systemic amyloidosis. Hippokratia. 2008 Oct;12(4):236-9.
Dember LM. Modern Treatment of Amyloidosis: Unresolved questions. J Am Soc Nephrol. 2008 Dec 10.
Gorevic, Shah, K. B., et al. Amyloidosis and the Heart. Archives of Internal Medicine. 2006. 166: 1805-1813.
P. D. An overview of amyloidosis. UpToDate.com
J D Sipe and Alan Cohen. Amyloidosis. Harrisons Principles of Internal Medicine. Chapter 30, page 2024
Images and tables were obtained from Harrisons, Archives of internal medicine, emedicine and google as sited on each image.